Collectively, our study confirmed that ACC1 pharmacological blockade significantly inhibits de novo fatty acid synthesis and CCA tumorigenesis, suggesting that WA may as a first-in-class targeted agent disrupting lipid metabolic rewiring for CCA treatment. The gene discussed is ACACA; the disease is cholangiocarcinoma.